10-Q: Ingevity Reports Q1 2025 Results, Adjusts Full-Year Outlook Amid Market Shifts

Ingevity Corporation's Q1 2025 results show a mixed performance with decreased net sales offset by improved profitability in certain segments, leading to an adjusted full-year outlook reflecting industry forecasts.

Summary

• Ingevity Corporation reported net sales of $284.0 million for the three months ended March 31, 2025, compared to $340.1 million for the same period in 2024.
• The decrease in net sales was primarily driven by the Performance Chemicals segment due to repositioning actions and weakness in industrial end markets.
• Gross profit increased to $113.4 million from $99.7 million, driven by decreased manufacturing costs and a LIFO liquidation benefit.
• The company's effective tax rate was 23.5% for the quarter.
• Adjusted EBITDA was $91.3 million, compared to $74.4 million in the prior year.
• The company has adjusted its full-year net sales outlook to between $1.25 billion and $1.4 billion, reflecting updated industry forecasts.
• The adjusted EBITDA outlook for 2025 is expected to be between $380 million and $415 million.
• The company realized cash savings of approximately $8 million in Q1 2025 from Performance Chemicals repositioning actions.
• The company expects to incur aggregate charges of approximately $360 million associated with the Performance Chemicals repositioning.
• The company expects to realize total cash savings of approximately $95 million to $100 million from the Performance Chemicals repositioning.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While there are positives such as increased gross profit and adjusted EBITDA, the decrease in net sales and adjusted full-year outlook temper the overall outlook.

Positives

• Gross profit increased due to decreased manufacturing costs and a LIFO liquidation benefit.
• Adjusted EBITDA increased year-over-year.
• The company is realizing cash savings from Performance Chemicals repositioning actions.
• Performance Materials segment EBITDA margins are expected to remain around 50 percent.
• Performance Chemicals reportable segment EBITDA is expected to improve due to revenue growth in our road technologies product line, lower CTO costs, and further savings from our repositioning actions.
• Advanced Polymer Technologies segment EBITDA will modestly improve versus prior year as our enacted pricing and mix strategies will produce segment EBITDA margins of around 20 percent.

Negatives

• Net sales decreased by 16% year-over-year.
• The company is adjusting the lower end of its previously disclosed outlook to Net sales between $1.25 billion and $1.4 billion for 2025.
• The adjusted EBITDA outlook, which has been adjusted to incorporate the ~10 percent reduction in North America light vehicle production, is expected to be between $380 million and $415 million for 2025.
• The company expects to incur aggregate charges of approximately $360 million associated with the Performance Chemicals repositioning.

Risks

• Adverse conditions in the automotive market may continue to negatively impact demand.
• The company faces competition from substitute products, new technologies, and new or emerging competitors.
• Lack of access to raw materials upon which the company depends would impact its ability to produce its products.
• The company may continue to be adversely affected by disruptions in its supply chain.
• The company is dependent on certain large customers.
• The company may be engaged in legal actions associated with its intellectual property rights.
• Government policies and regulations may adversely affect financial results.

Future Outlook

Ingevity expects net sales between $1.25 billion and $1.4 billion and adjusted EBITDA between $380 million and $415 million for 2025.

Management Comments

• The Performance Chemicals repositioning, which began in November 2023, is focused on reducing exposure to lower margin end-use markets of our industrial specialties product line.
• As a result of this initiative, we expect to realize total cash savings of approximately $95 million to $100 million.
• We are adjusting the lower end of our previously disclosed outlook to Net sales between $1.25 billion and $1.4 billion for 2025.
• Our Adjusted EBITDA outlook, which has been adjusted to incorporate the ~10 percent reduction in North America light vehicle production, is expected to be between $380 million and $415 million for 2025.

Industry Context

The adjusted full-year outlook reflects updated industry forecasts that estimate an approximate 10 percent reduction in North America light vehicle production, impacting the Performance Materials segment.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards.
• The document does not contain specific comparisons to comparable companies.
• The document does not contain specific comparisons to global benchmarks.

Management Changes

Legal Proceedings

• Ingevity is involved in ongoing legal proceedings with BASF Corporation regarding patent infringement and antitrust claims.
• The company has appealed the verdict in favor of BASF and the dismissal of its patent infringement claims.

Stakeholder Impact

• Shareholders may be impacted by the adjusted full-year outlook and the ongoing legal proceedings.
• Employees may be impacted by the Performance Chemicals repositioning and workforce reductions.
• Customers may be impacted by changes in product offerings and pricing.

Next Steps

• The company will continue to monitor the evolving macroeconomic landscape.
• The company will continue to focus on growing its most profitable Performance Chemicals product lines.
• The company will continue to diversify its raw material stream to non-CTO based fatty acids.

Key Dates

Keywords

Ingevity, financial results, Q1 2025, net sales, EBITDA, Performance Materials, Performance Chemicals, Advanced Polymer Technologies, restructuring, outlook